Paper42005248
Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy.
Sharma D and 3 others. Cureus, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy. Papers, record 42005248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42005248
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27402152 | A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association. | Acta Neuropathol Commun | 2016 | https://conductscience.org/library/papers/27402152 | PubMed |
| 2 | 37705970 | Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country. | Front Immunol | 2023 | https://conductscience.org/library/papers/37705970 | PubMed |
| 3 | 36706773 | Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. | Lancet Neurol | 2023 | https://conductscience.org/library/papers/36706773 | PubMed |
| 4 | 39901660 | Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. | Ann Clin Transl Neurol | 2025 | https://conductscience.org/library/papers/39901660 | PubMed |
| 5 | 30728305 | A multicenter comparison of MOG-IgG cell-based assays. | Neurology | 2019 | https://conductscience.org/library/papers/30728305 | PubMed |
| 6 | 34785575 | Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. | Neurol Neuroimmunol Neuroinflamm | 2022 | https://conductscience.org/library/papers/34785575 | PubMed |
| 7 | 32623596 | Cell-based assays for the detection of MOG antibodies: a comparative study. | J Neurol | 2020 | https://conductscience.org/library/papers/32623596 | PubMed |
| 8 | 40781064 | Reply to Letter: "Real-World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell-Based Assay". | Ann Clin Transl Neurol | 2025 | https://conductscience.org/library/papers/40781064 | PubMed |
| 9 | 29142145 | Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. | J Neurol Neurosurg Psychiatry | 2018 | https://conductscience.org/library/papers/29142145 | PubMed |
| 10 | 39981240 | Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review. | Front Immunol | 2025 | https://conductscience.org/library/papers/39981240 | PubMed |
| 11 | 34634625 | Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. | Mult Scler Relat Disord | 2021 | https://conductscience.org/library/papers/34634625 | PubMed |
| 12 | 40460615 | MOGAD treatment outcomes and relapse characteristics: Real world experience from a Low-Middle income country. | Mult Scler Relat Disord | 2025 | https://conductscience.org/library/papers/40460615 | PubMed |
| 13 | 40712508 | Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset. | Mult Scler Relat Disord | 2025 | https://conductscience.org/library/papers/40712508 | PubMed |
| 14 | 35785363 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. | Front Neurol | 2022 | https://conductscience.org/library/papers/35785363 | PubMed |
| 15 | 40717732 | Interleukin-6 targeting antibodies for the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): A review of current literature. | AIMS Neurosci | 2025 | https://conductscience.org/library/papers/40717732 | PubMed |
| 16 | 32304439 | Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. | Curr Opin Neurol | 2020 | https://conductscience.org/library/papers/32304439 | PubMed |
| 17 | 39778568 | Phenotype of Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children. | J Clin Neurol | 2025 | https://conductscience.org/library/papers/39778568 | PubMed |
| 18 | 36905816 | Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease. | Mult Scler Relat Disord | 2023 | https://conductscience.org/library/papers/36905816 | PubMed |
| 19 | 38314479 | Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. | Mult Scler | 2024 | https://conductscience.org/library/papers/38314479 | PubMed |
| 20 | 31266527 | Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. | J Neuroinflammation | 2019 | https://conductscience.org/library/papers/31266527 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MOG | 4340 | PubTator's text mining | https://conductscience.org/library/genes/4340 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42005248
GET https://conductscience.org/api/papers/v1/42005248/references?page=2